

FOI 4060

Treatment of Haematological Cancer

Answer the questions below in relation to the number of patients treated with specific medicines between the start of January 2026 to the end of March 2026, or the latest three-month period for which data is available. Include data for all hospitals in the Health and Social Care Trust.

Q1. How many patients were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? February 2026 – April 2026

Name of monotherapy or combination	Number patients treated
1.1 Glofitamab monotherapy	1
1.2 Glofitamab + Gemcitabine + Oxaliplatin	0

Q2. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? February 2026 – April 2026

Name of medicine	Number patients treated
2.1 Acalabrutinib (Calquence)	25
2.2 Ibrutinib (Imbruvica)	12
2.3 Pirtobrutinib (Jaypirca)	0
2.4 Venetoclax (Venclyxto)	14
2.5 Zanubrutinib (Brukinsa)	12
2.6 Rituximab	50
2.7 Obinutuzumab (Gazyvaro)	31

Q3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? February 2026 – April 2026

Name of medicine	Number patients treated
3.1 Acalabrutinib (Calquence)	25
3.2 Ibrutinib (Imbruvica)	7
3.3 Pirtobrutinib (Jaypirca)	0
3.4 Venetoclax (Venclyxto)	10
3.5 Zanubrutinib (Brukinsa)	1
3.6 Obinutuzumab (Gazyvaro)	2
3.7 Rituximab	3

Q4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? February 2026 – April 2026

Name of monotherapy or combination	Number patients treated
4.1 Ibrutinib + Venetoclax	2
4.2 Obinutuzumab + Venetoclax	6
4.3 Ibrutinib monotherapy / maintenance	5
4.4 Venetoclax monotherapy	0
4.5 Venetoclax + Rituximab	2
4.6 Rituximab monotherapy	0
4.7 Rituximab + Fludarabine + Cyclophosphamide	0
4.8 Rituximab + R-CHOP	0
4.9 Rituximab + Bendamustine	0
4.10 Rituximab + Chlorambucil	1
4.11 Obinutuzumab + Chlorambucil	0

4.12 Acalabrutinib + Venetoclax	0
4.13 Acalabrutinib + Venetoclax + Obinutuzumab	0

Q5. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? February 2026 – April 2026

Name of monotherapy or combination	Number patients treated
5.1 Acalabrutinib	0
5.2 Ibrutinib	3
5.3 Zanubrutinib	2
5.4 Ibrutinib + R-CHOP / R-DHAP	0
5.5 Pirtobrutinib	0